Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.59 USD | +7.87% | -1.29% | +7.49% |
Apr. 19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
Apr. 05 | Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication | MT |
Financials (USD)
Sales 2024 * | 88.57M | Sales 2025 * | 115M | Capitalization | 236M |
---|---|---|---|---|---|
Net income 2024 * | -96M | Net income 2025 * | -31M | EV / Sales 2024 * | 2.66 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.05 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-6.59
x | Employees | 274 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.5% |
Latest transcript on 2seventy bio, Inc.
1 day | +7.87% | ||
1 week | -1.29% | ||
Current month | -14.21% | ||
1 month | -14.21% | ||
3 months | +31.52% | ||
6 months | +113.49% | ||
Current year | +7.49% |
Managers | Title | Age | Since |
---|---|---|---|
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Susan Abu-Absi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Lynch
BRD | Director/Board Member | 65 | 21-10-14 |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.23% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 4.59 | +7.87% | 668,200 |
24-04-26 | 4.255 | -0.82% | 311,544 |
24-04-25 | 4.29 | +0.47% | 3,725,775 |
24-04-24 | 4.27 | -7.78% | 470,298 |
24-04-23 | 4.63 | -0.43% | 292,143 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.49% | 236M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- TSVT Stock